Enterprise Value
4.135M
Cash
42.99M
Avg Qtr Burn
-8.262M
Short % of Float
1.85%
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HEPA-CRV431-210 (rencofilstat) Details Non-alcoholic steatohepatitis , Hepatitis B | Phase 3 Initiation | |
HEPA-CRV431-207 (rencofilstat) Details Non-alcoholic steatohepatitis , Hepatitis B | Phase 2b Interim update |